Crohn's Disease Clinical Trial
Official title:
An Exploratory Study on the Impact of a Food-based Restrictive Diet (Crohn's Disease-TReatment-with EATing/CD-TREAT Diet) and Liquid Exclusive Enteral Nutrition (EEN) on Healthy Gut Microbiota Composition and Metabolic Activity
Current evidence suggests that the gut microbiota and dietary influences are as important as
genetics in the aetiology of Crohn's disease (CD). We have recently shown that disease
improvement, following treatment with Exclusive Enteral Nutrition (EEN), coincided with
changes in the gut microbiota.
The main purposes of this study are: a) to explore whether the gut microbiota changes we
observed in this previous study in children with CD during EEN are disease specific or not,
and b) to develop a novel food-based diet (Crohn's Disease TReatment-with-EATing/CD-TREAT
diet) which will induce changes to the metabolic activity and bacterial composition of the
gut microbiota of healthy people, similar to those seen on EEN, the first-line treatment for
active paediatric CD.
This study will produce high quality scientific evidence to move the CD-TREAT diet towards a
preliminary clinical trial in patients with CD which is currently inappropriate and
unethical to carry out in people with active CD undertaking contemporary medical treatment.
This study is a randomised, cross-over, dietary intervention trial. Healthy adult (>18 y)
participants from the community will be recruited by means of an advertisement leaflet and
word of mouth. Eligible participants will be enrolled in the study. We will thank those
subjects who have expressed an interest about the study but are not suitable to participate
and we will explain to them why they need to be excluded. Those who are eligible and willing
to participate will be asked to undertake two different experimental diets, for seven days
each:
1. Exclusive Enteral Nutrition (EEN) which is the exclusive consumption of a milk-based
proprietary dietary supplement (Modulen®, Nestle). This is a liquid based diet used for
the management of children with active CD. Although this diet is used primary for
clinical reasons it is food based and does not contain any drugs or non-food based
pharmaceutical ingredients. It is available online and without prescription from
pharmacist.
2. Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet), an elimination customized
diet which will consist of ordinary food and which will resemble the food/nutrient
composition of EEN (e.g. fibre content, fatty acid composition) and considering
evidence that implicates certain nutrients, and food ingredients (e.g. meat, sugar) in
the aetiology and risk of relapse of CD. Diet will be created using the food group
exchange methodology and will be analysed using Windiets® 2010.
Both diets will have the same energy content and will be isocaloric aiming to keep
participants' weight stable during the study period. Their energy content will be tailored
to participants' total energy expenditure and physical activity level calculated by the WHO
set of equations. The order of the diets will be randomly allocated using an MS Excel
command. In order to minimize fatigue with the diet but also to ensure that we will be able
to detect changes in gut microbiota, experimental diets will be given for 7 days. This is
based on recent evidence suggesting that dietary changes for 5 days induce reproducible
alterations in gut microbiota composition and metabolism. Prior to the first diet
intervention, participants will also record their dietary intake using a 7-day estimated
food diary. Between the two interventions the participants will have to eat their habitual
diet for two weeks and this will be a wash out period which aims to drive the gut microbiota
back to baseline levels. The week prior to the initiation of the second intervention the
participants will be asked to keep the same dietary pattern as they had the week prior to
the first trial.
Detailed methods:
Preliminary Health Check: Participants will undertake a short health questionnaire including
basic health information, age or any medication on the day of recruitment.
Anthropometry: All participants will have height and weight measured at baseline and only
weight measured in each sample collection timepoint.
Diet compliance: Over the course of the two experimental diets we will monitor compliance by
asking participants to complete a questionnaire. The questionnaire will ask if they felt the
need to supplement the diets at any time with other foods or drinks. An interval call 2 days
after each diet's initiation will also be used to increase participants' motivation and
compliance on the diets.
Sample collection & analysis: Fresh faecal and urine samples will be collected before and
after each dietary intervention (4 times in total) to assess and compare the impact of these
diets on gut microbiota composition and metabolic activity.
Lab Assays:
1. The gut bacterial diversity and composition from stool samples will be measured using
molecular techniques such as quantitative polymerase chain reaction (PCR) from
bacterial ribosomal DNA and next generation sequencing (metagenomics).
2. A large number of different products from bacterial metabolism, such as short chain
fatty acids, sulphide, and ammonia will be measured using a range of techniques
including gas chromatography and gas chromatography mass spectrometry
(GCMS)(metabolomics). Faecal pH, a marker of bacterial fermentation, will also be
measured.
Power calculation: Fresh faecal and urine samples will be collected from 38 healthy
participants at 4 time points. Based on our previous in vivo work in children with CD this
would give us a power of 80% (p=0.05) to detect a mean concentration difference of 1.0 log
(SD:1.5) in Faecalibacterium prausnitzii between their habitual diet and EEN diet or the
CD-TREAT diet.
;
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03815851 -
Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Surgery
|
N/A | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Completed |
NCT02883452 -
A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis
|
Phase 1 | |
Recruiting |
NCT04777656 -
Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients.
|
Phase 3 | |
Terminated |
NCT03017014 -
A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
|
||
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Recruiting |
NCT06053424 -
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease
|
Phase 1 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Terminated |
NCT02882841 -
MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients
|
N/A | |
Not yet recruiting |
NCT02858557 -
The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases
|
N/A | |
Completed |
NCT03010787 -
A First Time in Human Study in Healthy Volunteers and Patients
|
Phase 1 | |
Completed |
NCT02542917 -
Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study
|
||
Terminated |
NCT02417974 -
Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)
|
Phase 2 | |
Active, not recruiting |
NCT02316678 -
Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
|
N/A | |
Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
Completed |
NCT02193048 -
Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
|
||
Completed |
NCT02265588 -
Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD).
|
N/A | |
Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
Recruiting |
NCT02395354 -
Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease
|
N/A | |
Completed |
NCT01958827 -
A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease
|
Phase 3 |